These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 22117505

  • 1. Ambrisentan for sarcoidosis associated pulmonary hypertension.
    Judson MA, Highland KB, Kwon S, Donohue JF, Aris R, Craft N, Burt S, Ford HJ.
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct; 28(2):139-45. PubMed ID: 22117505
    [Abstract] [Full Text] [Related]

  • 2. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
    Saggar R, Khanna D, Shapiro S, Furst DE, Maranian P, Clements P, Abtin F, Dua S, Belperio J, Saggar R.
    Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
    [Abstract] [Full Text] [Related]

  • 3. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E, Hon S, Lawrence R, Berman J, Govender P, Farber HW.
    Sarcoidosis Vasc Diffuse Lung Dis; 2020 Dec; 37(2):234-238. PubMed ID: 33093789
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, Li Y, Wang Y, Ji QS, Zhu P, Wu BX, Zheng Y, Wang PP, Li J.
    BMC Cardiovasc Disord; 2016 Oct 22; 16(1):201. PubMed ID: 27770771
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M, Jing ZC, Li Y, Huo Y, Yu Z, Zhang G, Zhu P, Liu J, Ji Q, Wu B, Zhong J, Wang P, Zhu W, Zeng X.
    BMC Cardiovasc Disord; 2020 Jul 17; 20(1):339. PubMed ID: 32680480
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S, Shirato K, Shimamura R, Iwase T, Aoyagi N, Nakajima H.
    Curr Med Res Opin; 2012 Jun 17; 28(6):1069-76. PubMed ID: 22506623
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ.
    Respir Med; 2017 May 17; 126():84-92. PubMed ID: 28427554
    [Abstract] [Full Text] [Related]

  • 11. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD, Frost AE, Oudiz RJ, Badesch DB, Galie N, Olschewski H, McLaughlin VV, Gerber MJ, Dufton C, Despain DJ, Rubin LJ.
    Chest; 2009 Jan 17; 135(1):122-129. PubMed ID: 18812445
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
    Keir GJ, Walsh SL, Gatzoulis MA, Marino PS, Dimopoulos K, Alonso R, Raposeiras-Roubin S, Renzoni EA, Maher TM, Wells AU, Wort SJ.
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul 08; 31(2):82-90. PubMed ID: 25078636
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.
    Am J Cardiol; 2011 Jul 15; 108(2):302-7. PubMed ID: 21545989
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
    He J, Wen L, Jiang R, Zhao QH, Wang L, Jiang X, Yan P, Bai L, Jing ZC.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun 15; 41(6):493-6. PubMed ID: 24113042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.